

FUNDAPEN 2 Protocol

THE FACTS

- EpiPen® auto-injectors are available through the FundaPen2 initiative from Wednesday 9 February 2022.
- Target = prescriber-diagnosed allergy patients at risk of anaphylaxis
- 1 EpiPen® per eligible patient.
- The exclusive distributor is Queenstown Pharmacy (online = www.AllergyPharmacy.co.nz)

CONDITIONS

1. Every patient eligible for this offer needs to be prescriber-diagnosed with an allergy condition that puts them at risk of anaphylaxis.
2. Each recipient needs to receive training and education in the use of the EpiPen®, and management of their allergy to avoid anaphylaxis, from their prescriber.
3. Each EpiPen® prescribed under this initiative will be supplied at a fixed cost to Allergy New Zealand by using a single point of distribution – Queenstown Pharmacy
4. Only one FREE EpiPen® is available per eligible patient.

Each prescribed EpiPen® will be dispensed directly to your patient's postal address.

PROCESS

1. Establish that your patient is clinically eligible for FundaPen2.
2. Complete your patient's prescription for an EpiPen® as usual.
3. Add the word "FundaPen2" clearly on the prescription.
4. Include your patient's weight on the prescription so that the correct EpiPen® is dispensed.

To determine correct dose please reference ASCIA guidelines -

https://allergy.org.au/images/ASCIA_HP_Guidelines_Acute_Management_Anaphylaxis_2021.pdf

5. Please email the completed prescription to: info@queenstownpharmacy.co.nz
6. Queenstown Pharmacy assesses that the prescription meets the FundaPen2 eligibility criteria and dispenses the EpiPen® to the patient's address provided by the prescriber.
7. Please check your patient's postal address is accurate.

IMPORTANT

- It is the goal of Allergy NZ and Pub Charity to ensure as many eligible patients as possible benefit from the FundaPen2 initiative.
- Once 3,355 FREE EpiPen® auto-injector pens have been dispensed from Queenstown Pharmacy, normal prescribing protocols, distribution and fees apply.
- We invite your PHO to make your members aware of the FundaPen2 initiative ASAP.